Have a personal or library account? Click to login
Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors Cover

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors

Radiology and Oncology
Volume 50 (2016): Issue 3 (September 2016)
By: Tanja Dolinsek,  Lara Prosen,  Maja Cemazar,  Tjasa Potocnik and  Gregor Sersa  
Free to read
|Jul 2016

Figures & Tables

Figure 1

Survival of melanoma cells after vemurafenib (VMF) treatment. Survival of (A) BRAF V600E mutated melanoma cells SK-MEL-28 and (B) non-mutated melanoma cells CHL-1.
Survival of melanoma cells after vemurafenib (VMF) treatment. Survival of (A) BRAF V600E mutated melanoma cells SK-MEL-28 and (B) non-mutated melanoma cells CHL-1.

Figure 2

Survival of BRAF V600E mutated SK-MEL-28 melanoma cells and non-mutated CHL-1 cells after ECT with bleomycin. BLM (bleomycin); BLM + EP (ECT with bleomycin). Dotted line represents the IC90 value.
Survival of BRAF V600E mutated SK-MEL-28 melanoma cells and non-mutated CHL-1 cells after ECT with bleomycin. BLM (bleomycin); BLM + EP (ECT with bleomycin). Dotted line represents the IC90 value.

Figure 3

Survival of BRAF V600E mutated SK-MEL-28 melanoma cells after concomitant treatment with ECT and vemurafenib. BLM (bleomycin); BLM + VMF (bleomycin and 0.5 pM vemurafenib); BLM + EP (ECT with bleomycin); BLM + EP + VMF (ECT with bleomycin and 0.5 pM vemurafenib). Dotted line represents the IC90 value.
Survival of BRAF V600E mutated SK-MEL-28 melanoma cells after concomitant treatment with ECT and vemurafenib. BLM (bleomycin); BLM + VMF (bleomycin and 0.5 pM vemurafenib); BLM + EP (ECT with bleomycin); BLM + EP + VMF (ECT with bleomycin and 0.5 pM vemurafenib). Dotted line represents the IC90 value.
DOI: https://doi.org/10.1515/raon-2016-0042 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 274 - 279
Submitted on: May 23, 2016
|
Accepted on: Jun 14, 2016
|
Published on: Jul 19, 2016
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
electrochemotherapy,
BRAF inhibitors,
vemurafenib,
melanoma
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2016 Tanja Dolinsek, Lara Prosen, Maja Cemazar, Tjasa Potocnik, Gregor Sersa, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Previous articleVolume 50 (2016): Issue 3 (September 2016)Next article